Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new
approach to treating patients with certain blood cancers.
Patient Support Center
1 877 KARY4WD (1 877 527 9493)
|Access Date||Quiz Result||Score||Actions|
Please make sure the password is typed in ALL CAPS and includes the exclamation point. Enter the email address that you used to register for the conference.